Abstract

TAVR use is growing in patients with less than high surgical risk. Several registries, including this one, show excellent safety with TAVR in intermediate-risk patients compared with similar patients undergoing SAVR. Long-term data from ongoing randomized trials will answer definitively if we should routinely perform TAVR in intermediate-risk patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call